ABUS NASDAQ
Arbutus Biopharma Corp
1W: -8.2%
1M: -12.8%
3M: -10.5%
YTD: -6.7%
1Y: -3.0%
3Y: +121.4%
5Y: -3.7%
$4.45
-0.11 (-2.41%)
Weekly Expected Move ±3.6%
$4
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships8
As Filer
counterparties named
3
As Counterparty
mentioned by others
3
Rel. Types
2021-12-10
Earliest Filing
2026-03-23
Latest Filing
partner: 5
supplier: 2
acquirer: 1
Counterparties (Filed by ABUS)
8 relationshipsCompanies named in ABUS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Moderna | MRNA | acquirer | Paid $2.25 billion global settlement to resolve patent infringement claims regarding LNP delivery technology used in COV | 2026-03-03 | View |
| Roivant | ROIV | partner | Parent company of Genevant Sciences, which is a party to the settlement. | 2026-03-03 | View |
| Genevant | — | supplier | Received $950 million upfront and contingent payments for patent infringement related to LNP delivery technology. | 2026-03-03 | View |
| Arbutus | ABUS | supplier | Received $950 million upfront and contingent payments for patent infringement related to LNP delivery technology. | 2026-03-03 | View |
| Arbutus Biopharma Corporation | ABUS | partner | Entered into an exclusive licensing agreement and strategic partnership with Qilu Pharmaceutical to develop and commerci | 2021-12-13 | View |
| Qilu Pharmaceutical | — | partner | Partnered with Arbutus Biopharma to provide development, manufacturing, and commercialization expertise for AB-729 in ma | 2021-12-13 | View |
| Genevant Sciences GmbH | — | partner | Counterparty to Cross License Agreement amendment regarding IP infringement proceeds and sublicense revenue sharing | 2021-12-10 | View |
| Genevant Sciences Ltd. | — | partner | Parent company of Genevant Sciences GmbH, indirect wholly owned subsidiary | 2021-12-10 | View |
Mentioned As Counterparty
3 mentionsOther companies that named ABUS in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. | partner | Partner in patent litigation settlement with Roivant Sciences Ltd. | 2026-03-23 | View |
| MRNA Moderna, Inc. | partner | Settlement agreement to resolve patent infringement litigation involving lump sum and contingent payments | 2026-03-05 | View |
| ROIV Roivant Sciences Ltd. | partner | Partner in patent litigation settlement with Genevant Sciences GmbH. | 2026-03-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-21 | Other Events; Exhibits | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-16 | Termination of Agreement; Officer/Director Change; Other Events; Exhibits | View | |
| 2026-05-27 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-04-15 | Other Events; Exhibits | View | |
| 2026-03-23 | Earnings Release; Exhibits | View | |
| 2026-03-03 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-06 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-09-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-25 | Termination of Material Definitive Agreement; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-07 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR